RxDoctor Payments Data

William Mercer, MD

Family Medicine · Wheeling, WVNPI 1780687558

Payments from drug & device makers

$761in general payments, 2019–2025

Across 41 payments — averaging $18.55 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$155
  • Sanofi-aventis U.S. LLC$125
  • Amgen$99
  • Lilly USA, LLC$94
  • Novartis$63
  • Takeda Pharmaceuticals U.S.A., Inc.$42
  • plus $182 from 10 others

What the payments were for

  • Food & beverage$75599%
  • Education$51%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$761 in reported general payments places this provider in the 65th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$78,206
Medicare patients
174
Services billed
895

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
PromactaEltrombopag Olamine22$298,117
EliquisApixaban630$180,732
IngrezzaValbenazine Tosylate25$101,628
Enbrel SureclickEtanercept11$85,133
EpidiolexCannabidiol (Cbd)38$59,051
JardianceEmpagliflozin158$47,981
OzempicSemaglutide45$45,516
NuedextaDextromethorphan Hbr/Quinidine46$45,107
RexultiBrexpiprazole33$41,752
EntrestoSacubitril/Valsartan98$34,625
XareltoRivaroxaban105$29,218
FarxigaDapagliflozin Propanediol99$29,208
JanuviaSitagliptin Phosphate92$26,126
Trelegy ElliptaFluticasone/Umeclidin/Vilanter31$20,721
VraylarCariprazine Hcl21$20,634

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisPromacta, Entresto$63$332,742120 claims
PfizerEliquis, Premarin$14$186,132641 claims
GSKTrelegy Ellipta, Arexvy, Breo Ellipta, Shingrix$28$57,877153 claims
Boehringer IngelheimJardiance, Tradjenta$27$52,961177 claims
Novo NordiskOzempic$14$45,51645 claims
AbbVieVraylar, Restasis$18$35,41460 claims
Johnson & JohnsonXarelto$155$29,218105 claims
MerckJanuvia$16$26,12692 claims
Lilly USA, LLCTrulicity$94$17,62033 claims
Sanofi-aventis U.S. LLCLantus$125$6,68994 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Wheeling

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →